1033882-29-9 Usage
Uses
Used in Pharmaceutical Industry:
(R)-methyl 2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoate is used as a key intermediate in the synthesis of pharmaceutical compounds for [application reason]. Its unique structural features, including the chiral centers and diverse functional groups, make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-methyl 2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoate serves as a versatile compound for exploring novel drug candidates. Its structural complexity and chirality allow researchers to investigate its interactions with biological targets, potentially leading to the discovery of new therapeutic agents.
Used in Organic Synthesis:
(R)-methyl 2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoate is utilized as a synthetic building block in organic synthesis. Its functional groups and chiral centers enable the creation of a wide range of complex molecules, which can be further modified for various applications, including the development of new materials, catalysts, or pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1033882-29-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,3,8,8 and 2 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1033882-29:
(9*1)+(8*0)+(7*3)+(6*3)+(5*8)+(4*8)+(3*2)+(2*2)+(1*9)=139
139 % 10 = 9
So 1033882-29-9 is a valid CAS Registry Number.
1033882-29-9Relevant articles and documents
HCV PROTEASE INHIBITORS AND USES THEREOF
-
Page/Page column 54; 55, (2010/03/02)
This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.
